Skip to main content
. 2023 Jun 1;8(3):264–272. doi: 10.1089/trgh.2021.0130

Table 4.

Laboratory Assessment of Study Subjects with Pubertal Escape (n=8)

  Time of escape from HI placement (months, average±SD) LH (mIU/mL) T (ng/dL) Estradiol (pg/mL) GAHT HI outcome Escape biochemical/clinical
Group A (n=4) 33.3±21.6            
 A1 27 n/a   n/a Replaced Clinical (breast enlargement)
 A2 24 n/a 104   Replaced Biochemical
 A3 65 2.2 390 138 2 mg estradiol oral In place, added Lupron Biochemical and clinical (testicular enlargement, voice change)
 A4 7 0.93 20   Replaced (29 months) Biochemical
17 1.15 52  
21 0.9 34  
25 1.05 16 17 1.5 mg estradiol oral
Group B (n=4) 27.5±12.2            
 B1 28 n/a 51   75 mcg weekly transdermal estradiol Replaced Biochemical
 B2 44   64 106 4 mg estradiol oral In place, Increased estradiol Biochemical
 B3 23 0.09 182 3 12.5 mg SC-T bi-weekly Replaced Clinical (spotting)
 B4 15 0.97 80   In place, started estradiol Biochemical
All subjects (n=8)
Average, months±SD
30.4±16.5            

n/a, not available; SC-T, subcutaneous testosterone.